Los Angeles, July 2 -- A new study led by scientists at the U.S. National Institutes of Health (NIH) has found that two common forms of hormone therapy may alter breast cancer risk in women under the age of 55.
According to the study, women who received unopposed estrogen hormone therapy (E-HT) had a lower risk of developing breast cancer compared to those who did not use hormone therapy. In contrast, women treated with combined estrogen plus progestin hormone therapy (EP-HT) were found to have a higher risk of developing the disease.
The findings, published Monday in The Lancet Oncology, are based on an extensive analysis of data from over 459,000 women under the age of 55 across North America, Europe, Asia and Australia.
"Our study ...